Effect of a GnRH vaccine formulation on testosterone concentrations and reproduction in adult male rats

Franklin Fuentes¹, Jesús Junco¹, Lesvia Calzada¹, Yovisleydis Lopez², Eulogio Pimentel¹, Roberto Basulto Baker¹, Osvaldo Reyes Acosta², Hilda E Garay-Pérez², Gerardo Guillén-Nieto²

¹ Centro de Ingeniería Genética y Biotecnología de Camagüey
Carretera Circunvalación Norte Apdo Postal 387, Camagüey, Cuba
² Centro de Ingeniería Genética y Biotecnología
Ave 31 e/ 158 y 190, Cubanacán, Playa. Apdo Postal 6072. CP 10600, La Habana, Cuba
franklin.fuentes@cigb.edu.cu

The effect of different doses of the gonadotropin releasing hormone (GnRH) mimetic peptide GnRHm1-TT is described, administered in three immunization schemes to define the most effective alternative combination for the treatment of prostate cancer. The design elements of the peptide immunogens are the GnRH-m1 linked to a T helper epitope of tetanus toxoid (TT) by chemical synthesis. Three doses of peptide GnRHm1-TT: 125, 300 and 750 μg were formulated in oil-based emulsions and tested in Copenhagen rats. Three immunization schemes (weekly, fortnightly and monthly) were used. As a result, the 750 μg dose generated a specific anti-GnRH antibody response in the fortnightly and monthly schemes, in contrast to 125 μg and 300 μg doses. The anti-GnRH seroconversion in the best responders corresponded with a decline, both in the testosterone levels down to castration and the size and weight of reproductive organs, an effect absent for the remaining doses of the three immunization schemes. The best variant corresponded to the 750 μg dose in a monthly regime. These findings demonstrated a marked immune-neutralization of the GnRH hormone for a subsequent immunological castration.

Keywords: cancer vaccine, GnRH, rats, castration, testosterone

Biotecnología Aplicada 2014;31:222-22

Introduction

Several treatment options exist for different stages of prostate cancer including observation, prostatectomy, radiation therapy, chemotherapy, and hormone therapy. Hormone therapy has evolved from the use of estrogens to gonadotropin-releasing hormone (GnRH) agonists and GnRH antagonists. GnRH analogs are widely used to block hypothalamic pituitary axis and therefore, represent the treatment of choice for prostate cancer patients. GnRH receptors are expressed in prostate cancer, even when the tumor has reached the castration resistant prostate cancer stage, and are endowed with antitumor activity, supporting the notion that they might be a molecular target for GnRH analog-based therapeutic strategies.

GnRH is a 10-amino acids peptide hormone which is secreted by the hypothalamus and transported by the hypothalamic hypophysial portal system to the anterior pituitary. This hypothalamic peptide hormone controls the synthesis and secretion of sex steroid hormones (testosterone in males and estradiol and progesterone in females) and thus controls the whole reproductive function [1-3]. Testosterone is considered essential for the growth of prostate tumors. Within the prostate cells, testosterone is converted into 5α-dihydrotestosterone (DHT), by the action of the 5α-reductase enzyme. As an intracellular androgen, DHT is approximately 10 times more powerful than testosterone. The production of the primary

circulating androgen, testosterone, relies on the interplay of the hypothalamic-pituitary axis and the testes.

GnRH-based vaccines represent a promising anti-hormonal treatment alternative in prostate cancer, because these can reduce serum testosterone to castration levels. In turn, the ability to generate a memory immune response in vaccinated patients allows them to be without medication for relatively long periods of time, which also results in lower medication costs and marketing. This aspect gives vaccines high added-value and great competitiveness in the market [5].

An alternative approach to the use of GnRH analogs is the immunization with the native or a mimetic GnRH to induce anti-GnRH antibodies that may neutralize its biological activity, resulting in castration effects similar to those of GnRH drug therapy. In fact, immunization against GnRH has been shown to interrupt these biological activities in male mice [7].

GnRH immunogens have been reported to cause suppression in testicular activity in bovine for a long time [8, 9]. They can also be used to suppress reproductive functions in swine, as was the case of the GnRH dimmer in tandem conjugated to ovalbumin (OVA) and emulsified in Specol [10]. This vaccine was highly immunogenic in healthy animals, inducing high anti-GnRH antibody titers and resulting in decreased testosterone levels, particularly significant in prostate and testicles weight reduction in pigs, dogs, and rats [11].

Furthermore, since GnRH is a short peptide, immunoenhancing approaches have to be implemented for successful vaccination. One of the most common procedures to make a peptide immunogenic is to couple it to a carrier protein molecule, such as: KLH, TT, diphtheria toxoid (DT), OVA, bovine and human serum albumin (BSA and HAS, respectively). Moreover, the origin of the carrier protein could be relevant for the conjugate immunogenicity levels, with heterologous proteins expected to result in conjugates of stronger immune responses. In general, several heterologous proteins can be used as carriers, but non-mammalian proteins tend to be highly immunogenic.

Additionally, the site of conjugation may determine the efficacy of the immunization [6]. The conjugation process used for the peptide-carrier fusion has caused losses during conjugation and made the goals [6]. Recently, multiple T-helper epitopes were chemically bound to GnRH to improve the immunogenicity and the castration levels in potential recipients [13]. It was shown that two immunizations with the G6k-GnRH tandem-dimer-OVA conjugate in a suitable adjuvant such as CoVaccine™HT causes a rapid and complete reduction of serum testosterone levels in sexually mature stallions [14]. It subsequently led to reduced sperm motility and affected testis function, while no adverse reactions were observed after immunizations. In a mouse model, it was demonstrated that anti-GnRH antibody responses can be induced by a synthetic GnRH3-hinge-MVP peptide. Mice treated with GnRH3-hinge-MVP-hsp65 had a significantly prolonged survival and suppression of local tumor growth, also showing reduced serum testosterone and luteinizing hormone levels (p < 0.05) [15].

The strategy was to induce immunity to GnRH by altering the target molecule on a synthetic peptide conjugated to TT immunogen (GnRHm1-TT) [16]. In this work, its immunogenic capacity and its correlation with a reduction in testosterone levels in a rat model was determined, using three doses and three immunization schemes. Our results are relevant for future clinical trials in prostate cancer patients.

**Materials and methods**

**Peptide synthesis**

Peptides were synthesized on an AKTA 100 (GE Healthcare USA, Piscataway, NJ, USA) HPLC system. Separation was achieved in an RP-C18 column (4.6 × 150 mm, 5 μm) (Vydac, Grace, Deerfield, IL, USA), with solvents: A (0.1% of TFA in water) and B (0.05% of TFA in acetonitrile). A linear gradient of 5-60% of B for 35 min and a flow rate of 0.8 mL/min were used. Chromatograms were acquired at 226 nm, using the software package Unicorn 4.11 (GE Healthcare USA) for data processing of the RP-HPLC chromatograms. Peptides were scrutinized on a LaChrom (Merck Hitachi, Darmstadt, Germany) HPLC system, using an RP-C18 column (Vydac, 25 × 250 mm, 25 μm) and a flow rate of 2 μL/min. Absorbance was monitored at 226 nm.

**Animal models**

Seventy-seven male Copenhagen rats of 8-9 weeks of age and females untreated for breeding were used. The animals were kept under a controlled environment at 20 °C, 65% relative humidity and a 14 h light/10 h dark photoperiod. Water and sterile feed access was ad libitum.

The animals were distributed at random in 11 experimental groups (7 rats each). Three doses of the GnRHm1-TT peptide were used: 125, 300 and 750 μg; and three schemes for each dose (weekly, fortnightly and monthly). Additionally, a group of castrated and placebo animals were used.

**Immunogen preparation, immunization and mating**

The GnRHm1-TT peptide was suspended in phosphate buffered saline (PBS; v/v) and added, drop-by-drop, to the vaccine formulation. In this study, the solid phase synthesis and chemical coupling of the GnRHm1-1TT peptide to the 17 amino acid sequence 830-844 of TT trough their carboxy-terminal using a glycine-glycine (GG) spacer.

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Primary structure of the native GnRH molecule and the GnRHm1-TT peptide. The GnRHm1-TT molecule is the result of the solid phase synthesis and chemical coupling of the GnRH1 molecule with a tetanus toxoid (TT) epitope. The synthetic process was carried out coupling the GnRH1 peptide to the 17 amino acid sequence 830-844 of TT trough their carboxy-terminal using a glycine-glycine (GG) spacer.


to the same volume of Montanide ISA 51 v/v. It was further shaked for 30 min to prepare the emulsion. Emulsions were prepared just before immunization.

Every scheme had rounds of 4 immunizations. The immunogens (500 µL) were administered subcutaneously on 4 sites along the supraescapular area, on both sides of the spine. The placebo animals were mated 4 weeks after the last vaccination with adult Copenhagen female rats. On the contrary, the males from the weekly scheme were mated after the last vaccination. The pairs (one per cage) stayed together for 2 weeks. Then, treated and untreated males were removed and anesthetized prior to sacrifice by cervical dislocation. The progenies from the pairs were registered and weighed.

**Blood and serum collection and animal weighing**

Blood was collected intraorbital puncture (500 µL approx.) and the animals were weighed, in all the schemes before each immunization, a week after the last immunization and on the day of sacrifice. The blood was centrifuged at 3200 rpm for 30 min, and sera collected and stored at –20 ºC until use.

**Anti-GnRH antibody titer screening**

The concentration of circulating GnRH-specific antibodies was determined by enzyme-linked-immunosorbent assay (ELISA). Solid-phase ELISA was performed using 96-well polystyrene plates (High binding, Nunc), coated with 10 µg/mL of natural GnRH peptide overnight at 4 ºC. Subsequently, plates were blocked with PBS (pH 7.4) supplemented with bovine serum albumin (BSA, 2 % v/v; Sigma) for 60 min at 37 ºC, and further washed three times with PBS-Tween 20 at 0.05 %. Then, the diluted serum samples were incubated 3 h at 37 ºC. After the corresponding washes, the anti-IgG antibodies against the GnRHm1-1 peptide conjugate was added to the working solution (1/8000) and plates were incubated for 60 min at 37 ºC. The reaction of anti-IgG antibodies against the GnRHm1 peptide was detected by adding orthophenylenediamine (OPD) as chromogen and the H2O2 substrate dissolved in a proper buffer (dibasic sodium phosphate 0.02 M, pH 5) and incubated for 30 min at room temperature. Finally, the reaction was stopped by the addition of 2.5 N sulphuric acid. The plates were read at 492 nm with the microtiter plate reader (Multiscan, Labystem, Finland). Samples with absorbance values greater than the cut off line (0.159) were considered positive.

The immune response kinetics was calculated from the mean anti-GnRH antibody seroconversion for each experimental group. Sera were diluted 1/50, as the maximum absorbance value. The cut off value of the test (0.159) was calculated from a set of negative samples [18].

**Testosterone determination**

Testosterone levels were determined using the commercial TESTO CT2 kit, (CIS Bio International France). The sensitivity of the method, as defined as the detectable concentration equivalent to twice the standard deviation of the zero-binding value, was approximately 0.1 nmol/L, with a specificity of the test kit for testosterone higher than 99 %. Determinations were done in duplicates, by plating 25 µL of each serum sample directly in the pre-coated tubes, followed by incubation for 1 h at 37 ºC. Finally, the tubes were washed with distilled water and read in a gamma counter, with results expressed in nmol/L.

**Macrosopic evaluation of reproductive organs**

Animal testicles and prostates were removed and weighed on an analytical balance (Sartorius) and standardized against animals weights.

**Statistical analysis**

A multifactorial variance analysis was used, followed by a Duncan’s multiple range test (95 % confidence interval, p > 0.05).

The F ratio was set as 5.27844, calculated as the ratio between-groups estimate over the within-groups estimate, with estimates coming from the ANOVA variance data table. A p value lower than 0.05 was used for the F test, to fit the statistical differences between the means of the three variables at a 95 % confidence interval, and differences were determined by Multiple Range comparison test.

**Results**

**Anti-GnRH antibodies seroconversion**

The means of anti-GnRH antibodies seroconversion against the peptides used for immunization are shown in figure 2. The highest seroconversion values (absorbance at 492 nm) were obtained in the experimental group receiving 750 µg of the GnRHm1-TT peptide monthly and fortnightly; whereas for the 300 µg dose in the three schemes, seroconversion values were discretly higher than the cut off line.

**Testosterone levels**

Regarding testosterone levels, it was observed that the 750 µg dose of GnRH m1-TT was the only one able to reduce testosterone values under castration levels (1.7 nmol/L) in the fortnightly and monthly immunization schemes, with the highest reduction in the monthly immunization scheme. Significant differences were achieved with this dose compared to the 125 µg (p = 0.0001), 300 µg (p = 0.0243) and placebo (p = 0.0013). Animals receiving 300 µg of the peptide only showed significant differences in testosterone levels in the monthly scheme, compared to those immunized with 125 µg (p = 0.021) and placebo (p = 0.0443) (Figure 3), but never reached castration levels. The immunization with 125 µg of GnRH m1-TT neither reduced testosterone levels below castration levels nor generated statistically significant differences with those of the placebo group.

**Crossings**

Fertility of immunized males was tested 15 days after the last GnRHm1-TT injection. Parallel studies were conducted with control males. The fertility data from pregnant rats are shown in the table. In the 750 µg dose groups in fortnightly and monthly immunization schemes, 1 out of 7 males (14 %) was fertile in both schemes. The rest of the experimental groups showed no significant differences from controls.

**Post-mortem analysis of organs**

The relation between testis and prostate weight and average GnRH binding percentage per animal

1.2 Immunizations

A tide antigen used which is similar to the endogenous species, like swine and rats, have shown that the pep however, the results from the studies made in some the most prominent alternatives to surgical castration; in a rat model, which was determined by using three studying the immunogenic capacity of GnRHm1-TT production at the testicle level. This was the basis for the release of gonadotropin, necessary for testosterone mally joins the receptor of the hypophysis and causes homologous model for the human GnRH [4]. It nor

gnRH is a peptide showing a fully conserved structure throughout mammalian species, and serves as a homologous model for the human GnRH [4]. It normally joins the receptor of the hypophysis and causes the release of gonadotropin, necessary for testosterone production at the testicle level. This was the basis for studying the immunogenic capacity of GnRHm1-TT and the correlation with reduced testosterone levels in a rat model, which was determined by using three doses and three immunization schemes.

The active immunization against GnRH is one of the most prominent alternatives to surgical castration; however, the results from the studies made in some species, like swine and rats, have shown that the peptide antigen used which is similar to the endogenous GnRH was poorly immunogenic, an effect related with the haptenic nature of GnRH [19].

The administration of a GnRH-based formulation causes changes or damage in most of the organs of the reproductive system of mammals, markedly reducing the levels of circulating testosterone that leads to castration levels as the essential condition to achieve formulation efficiency [20].

Considering the natural tolerance to GnRH due to its conservation in mammals, a GnRH analogue variant was created with an aminoacid change of a glycine for a proline, and one T helper epitope from TT to increase the GnRH immunogenic capacity [16]. The different doses tested of the vaccine candidate in three different immunization schemes showed the best anti-GnRH antibody seroconversion results when administering 750 µg in a monthly scheme. In the groups receiving 125 µg and 300 µg doses antibody

**Discussion**

Table. Experimental group and immunization scheme distribution of adult male rats immunized with a gonadotropin releasing hormone (GnRH) variant linked to a tetanus toxoid helper epitope (GnRHm1-TT) peptide

<table>
<thead>
<tr>
<th>Groups</th>
<th>Weekly scheme</th>
<th>Fortnightly scheme</th>
<th>Monthly scheme</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Animals</td>
<td>Immunizations</td>
<td>Animals</td>
</tr>
<tr>
<td>125 µg</td>
<td>6</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>300 µg</td>
<td>7</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>750 µg</td>
<td>7</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>Control</td>
<td>9</td>
<td>7</td>
<td>9</td>
</tr>
</tbody>
</table>

* Significant differences of animal fertility compared to the control.

levels did not surpass the ELISA cut off line either the scheme. The phenomenon observed in these lower doses seems to correspond to the poor immunogenicity expected for an autologous, low molecular weight molecule like GnRH. Although it has been altered and coupled to an immunogenic carrier, it needs to be administered to attain antigen concentrations enough to mount effective immune activation, as determined by Talwar [4]. Alternatively, the low immunogenicity regarding all the doses in the weekly scheme seems to be related to a low maturation of the immune response, due to the huge antigenic load provided in terms of immunization frequency. Ultimately, the natural hormone is immunoneutralized by the generated anti-GnRH antibodies.

A direct correlation was observed between the anti-GnRH antibody seroconversion achieved with the 750 µg dose and the decrease in testosterone levels down to castration. Nevertheless, a similar effect was seen in the fortnightly scheme using the same dose, regardless the discrete anti-GnRH antibody seroconversion. In the weekly scheme, testosterone levels remained steady for any of the doses tested, in agreement with previous reports [4, 14, 20].

Post-mortem analysis of testicles and prostates of animals immunized with the 750 µg dose in the monthly scheme revealed a significant weight reduction of testicles and prostates compared to those of the control animals.

Additionally, there was a small, but significative decrease in prostate weight in the animals receiving the 750 µg and 300 µg doses in the fortnightly scheme; however, testicles weight did not varied the same [22]. No signs of biological effects in gonads and accessory glands were observed in the weekly scheme.

The weight decrease and atrophy in testicles and prostate of the animals immunized with GnRH modified variant suggest the entanglement of antibody-mediated GnRH neutralization, which subsequently deplete gonadotrophic hormones (luteinizing hormone and follicle-stimulating hormone) which play an important role in the normal development of the genital apparatus [23]. When the reproductive capacity of the animals in the different experimental groups was checked, the 750 µg dose in the fortnightly and monthly schemes induced an infertility process that may be caused mainly by a reduction in testosterone levels as essential hormone for spermatogenesis in males. These results greatly correlated with anti-GnRH antibodies, animal’s andrology and post-mortem analysis. It is suggested that reproductive organ atrophy would have caused of animal infertility.

There can be concluded that the best administration dose and immunization scheme combination is the 750 µg dose administered in a monthly scheme. This is a relevant result, considering it establishes the effective dose and immunization regime to develop a therapeutic vaccine against human hormone-dependent neoplasia, like prostate and breast cancer, of high incidence worldwide [24].

This vaccine candidate represents a promising anti-hormonal alternative in prostate cancer treatment. In turn, the potential to generate a memory immune response in vaccinated patients provides a therapeutic strategy without medications for relatively long periods of time which would also result in lower medication and marketing costs.